Ivana Apicella Selected Research

Macular Degeneration (Age-Related Maculopathy)

12/2021	DDX17 is an essential mediator of sterile NLRC4 inflammasome activation by retrotransposon RNAs.
10/2021	Identification of fluoxetine as a direct NLRP3 inhibitor to treat atrophic macular degeneration.
10/2021	Alu complementary DNA is enriched in atrophic macular degeneration and triggers retinal pigmented epithelium toxicity via cytosolic innate immunity.
1/2021	Cytoplasmic synthesis of endogenous Alu complementary DNA via reverse transcription and implications in age-related macular degeneration.
1/2021	Nucleoside reverse transcriptase inhibitors and Kamuvudines inhibit amyloid-β induced retinal pigmented epithelium degeneration.
1/2020	A Clinical Metabolite of Azidothymidine Inhibits Experimental Choroidal Neovascularization and Retinal Pigmented Epithelium Degeneration.
1/2020	Chronic Dicer1 deficiency promotes atrophic and neovascular outer retinal pathologies in mice.
1/2018	cGAS drives noncanonical-inflammasome activation in age-related macular degeneration.
1/2016	Intravenous immune globulin suppresses angiogenesis in mice and humans.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ivana Apicella Research Topics

Disease

9	Macular Degeneration (Age-Related Maculopathy) 12/2021 - 01/2016
5	Pathologic Neovascularization 04/2021 - 04/2014
4	Blindness (Hysterical Blindness) 10/2021 - 01/2018
4	Choroidal Neovascularization 04/2021 - 04/2015
4	Neoplasms (Cancer) 05/2018 - 03/2014
3	Geographic Atrophy 10/2021 - 01/2018
2	Colorectal Neoplasms (Colorectal Cancer) 01/2016 - 04/2015
1	Retinal Detachment (Retinal Detachments) 01/2023
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 12/2021
1	Noncommunicable Diseases 12/2021
1	Retinal Degeneration 12/2021
1	Ischemia 04/2021
1	Atrophy 01/2020
1	Autoimmune Diseases (Autoimmune Disease) 01/2016
1	Fibrosarcoma 01/2016
1	Corneal Neovascularization 01/2016
1	Hypoxia (Hypoxemia) 04/2014
1	T-Cell Leukemia (Leukemia, T Cell) 03/2014

Drug/Important Bio-Agent (IBA)

8	Retinaldehyde (Retinal)IBA 01/2023 - 01/2018
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2018 - 04/2014
3	InflammasomesIBA 12/2021 - 01/2018
2	ElementsIBA 12/2021 - 01/2018
2	Complementary DNA (cDNA)IBA 10/2021 - 01/2021
2	RNA (Ribonucleic Acid)IBA 01/2021 - 01/2018
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2018 - 04/2014
1	Interleukin-18 (Interleukin 18)IBA 12/2021
1	Fluoxetine (Prozac)FDA LinkGeneric 10/2021
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2021
1	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 04/2021
1	NucleosidesIBA 01/2021
1	Amyloid (Amyloid Fibrils)IBA 01/2021
1	Zidovudine (Retrovir)FDA LinkGeneric 01/2020
1	3'- azido- 3'- deoxy- 5'- O- beta- glucopyranuronosylthymidineIBA 01/2020
1	Ribonucleases (Ribonuclease)IBA 01/2020
1	MicroRNAs (MicroRNA)IBA 01/2020
1	InterferonsIBA 01/2018
1	Retroelements (Retrotransposon)IBA 01/2018
1	Intravenous Immunoglobulins (IVIG)FDA Link 01/2016
1	Monoclonal AntibodiesIBA 04/2015
1	Irinotecan (Camptosar)FDA LinkGeneric 04/2015
1	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 04/2015
1	Bevacizumab (Avastin)FDA Link 04/2015
1	Peptides (Polypeptides)IBA 04/2015
1	Histones (Histone)IBA 04/2014
1	ThioredoxinsIBA 03/2014
1	atractyligenineIBA 03/2014
1	ent-kaurane 15-ketoatractyligenin methyl esterIBA 03/2014

Therapy/Procedure

4	Therapeutics 10/2021 - 01/2016
4	Lasers (Laser) 04/2021 - 04/2015
1	Intravitreal Injections 04/2015